<DOC>
	<DOC>NCT00406380</DOC>
	<brief_summary>Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias</brief_summary>
	<brief_title>Effect of Avastin in Juxtafoveal Telangiectasias</brief_title>
	<detailed_description>After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion Patients with Idiopathic Juxtafoveal Retinal Telangiectasias Diabetic Retinopathy and Diabetic Macular Edema Hypertensive Retinopathy Choroidal Neovascularization</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Telangiectasias</keyword>
	<keyword>Leakage</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Telangiectasias secondary to Branch Retinal Vein Occlusion (BRVO)</keyword>
	<keyword>Idiopathic juxtafoveal retinal telangiectasias</keyword>
</DOC>